Flag of the European Union EU Clinical Trials Register Help

Clinical trials for multiple sclerosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    631 result(s) found for: multiple sclerosis. Displaying page 23 of 32.
    «« First « Previous 19  20  21  22  23  24  25  26  27  Next» Last»»
    EudraCT Number: 2012-004165-41 Sponsor Protocol Number: STH16542 Start Date*: 2013-11-04
    Sponsor Name:Northwestern University
    Full Title: Hematopoietic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study
    Medical condition: Inflammatory Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000411-91 Sponsor Protocol Number: NKZellen-Version1.0 Start Date*: 2013-02-13
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial
    Medical condition: relapsing-remitting multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005076-34 Sponsor Protocol Number: BEL-FMP-12-10325 Start Date*: 2013-01-03
    Sponsor Name:Cliniques Universitaires Saint-Luc, Neurologie
    Full Title: Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters. A cross-over, double-blinded, placebo-controlled study.
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001540-23 Sponsor Protocol Number: 309560 Start Date*: 2006-03-03
    Sponsor Name:Schering Nordiska AB
    Full Title: A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis.
    Medical condition: Early Secondary Progressive Multiple Sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-004736-79 Sponsor Protocol Number: 1102-CT02 Start Date*: 2007-03-06
    Sponsor Name:Antisense Therapeutics Ltd.
    Full Title: A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous inje...
    Medical condition: To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-003418-15 Sponsor Protocol Number: SSP Start Date*: 2012-10-23
    Sponsor Name:Medizinische Universität Wien
    Full Title: Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center randomized double-blind placebo-controlled trial.
    Medical condition: Fatigue is a very common symptom in multiple sclerosis. Its management comprises nonpharmacologic approaches like exercise, cooling procedures and energy conservation programs and as second step ph...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001956-12 Sponsor Protocol Number: NT12385-5 Start Date*: 2011-05-25
    Sponsor Name:University Hospital Motol
    Full Title: Monitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with Multiple Sclerosis.
    Medical condition: To correlate bioactivity of IFNβ reflected by level of MxA expression and clinical course of MS To measure expression of MxA protein in patients treated with IFNβ depending on NAbs status NAbs p...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004731-76 Sponsor Protocol Number: LTS16004 Start Date*: 2019-12-06
    Sponsor Name:Genzyme Corporation
    Full Title: Long-term extension safety and efficacy study of SAR442168 in participants with relapsing multiple sclerosis
    Medical condition: Relapsing multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) SK (Completed) CZ (Completed) EE (Completed) ES (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005265-11 Sponsor Protocol Number: GWMS0501 Start Date*: 2006-04-03
    Sponsor Name:GW Pharma Ltd
    Full Title: A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sc...
    Medical condition: Relief of central neuropathic pain in subjects with multiple sclerosis (MS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-005989-37 Sponsor Protocol Number: 308841 Start Date*: 2006-03-29
    Sponsor Name:Schering Oy
    Full Title: CogniMS: observational study to assess cognition in patients with early Multiple Sclerosis
    Medical condition: Observational Study to assess cognition in patients with early Multiple Sclerosis. Relapsing-Remitting MS-patients diagnosed within 2 years and who have started the Betaferon treatment (interferon-...
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005211-21 Sponsor Protocol Number: 2005/00804 Start Date*: 2006-01-17
    Sponsor Name:Schering Oy
    Full Title: A long term follow up of relapsing remitting multiple sclerosis patients who have been treated with intereron beta -1b (Betaferon) at least 5 years
    Medical condition: Remitting relapsing multiple sclerosis (RRMS) is one of the most common diseases of the central nervous system. The cause of MS is not yet known but it is a result of damage to myelin. Symptoms var...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005450-30 Sponsor Protocol Number: ABI-MS-P01 Start Date*: 2014-01-08
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment
    Medical condition: Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011088-35 Sponsor Protocol Number: PACAMUS Start Date*: 2010-03-24
    Sponsor Name:Philipps-Universität Marburg
    Full Title: Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAM...
    Medical condition: Patients with Multiple Sclerosis (MS) or Clinically isolated syndrome suggestive for MS (CIS) are investigated. The main objective is to conserve data about changes in the VIP/PACAP (vasoactive int...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002683-24 Sponsor Protocol Number: CP-NU100-01.00 Start Date*: 2012-01-30
    Sponsor Name:Nuron Biotech, Inc.
    Full Title: A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis
    Medical condition: Relapsing forms of multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-007447-14 Sponsor Protocol Number: 222500 Start Date*: 2009-04-03
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: GH-IGF-I status and Multiple Sclerosis: clinical implications (a prevalence study).
    Medical condition: patients with Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10022891 Investigations SOC
    14.1 10014698 - Endocrine disorders 10014698 Endocrine disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000001-23 Sponsor Protocol Number: DroSpas-1 Start Date*: 2018-10-25
    Sponsor Name:Bionorica SE
    Full Title: A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in pat...
    Medical condition: Symptomatic relief of spasticity in patients with multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2023-000018-16 Sponsor Protocol Number: OZA22/IM047-048 Start Date*: 2023-04-19
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study
    Medical condition: Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004116-38 Sponsor Protocol Number: RIFUND-MS Start Date*: 2015-12-18
    Sponsor Name:Department of Clinical Sciences, Danderyd Hospital
    Full Title: RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis – RIFUND-MS A randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis Ob...
    Medical condition: Patients with multiple sclerosis (MS) or patients presenting with symptoms highly suspicious of MS while not completely fulfilling diagnostic criteria, 18 - 50 years of age and no more than 10 year...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005899-36 Sponsor Protocol Number: CLOU064C12301 Start Date*: 2022-02-21
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) LT (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001511-73 Sponsor Protocol Number: WA40404 Start Date*: 2019-12-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
    Medical condition:
    Disease:
    Population Age: Gender:
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) PT (Trial now transitioned) IE (Completed) DE (Completed) BG (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) HU (Completed) HR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 19  20  21  22  23  24  25  26  27  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 14:44:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA